特发性炎性肌病患者皮下注射免疫球蛋白:一项真实世界单中心经验
该研究回顾性分析了20例从静脉注射免疫球蛋白(IVIG)转为皮下注射免疫球蛋白(SCIG)治疗超过12个月的特发性炎性肌病患者,78.9%的患者更偏好SCIG,SCIG启动前后12个月整体疾病活动度(MITAX 3.31 vs 3.02)和累积泼尼松剂量无显著差异,3例出现疾病复发。
要点
- 78.9%的特发性炎性肌病患者更偏好SCIG而非IVIG,并偏好居家治疗而非医院治疗。
- SCIG启动前后12个月整体疾病活动度(MITAX 3.31 vs 3.02)无显著差异。
- SCIG启动前后12个月累积类固醇剂量无显著差异,3例出现疾病复发。
核心结论
- 大多数患者更偏好SCIG而非IVIG,且未出现疾病活动度大幅增加或需要额外使用皮质类固醇。
- 未来的成本效益研究可能为使用SCIG而非IVIG作为特发性炎性肌病维持治疗提供额外依据。
研究设计与样本
- 回顾性审查了连续20例从IVIG转为SCIG治疗超过12个月的特发性炎性肌病患者。
- 采用先前用于神经炎性疾病研究的问卷进行调查患者对IVIG与SCIG的偏好。
- 使用肌炎意向治疗指数(MITAX)评估SCIG启动前后12个月的疾病复发、免疫抑制变化、累积泼尼松剂量和整体疾病活动度。
主要发现
- 大多数患者(78.9%)偏好SCIG而非IVIG,并偏好居家治疗而非医院治疗。
- SCIG启动前后12个月整体疾病活动度无显著差异(MITAX 3.31 vs 3.02)。
- SCIG启动前后12个月累积类固醇剂量无显著差异。
- 3例患者出现疾病复发,5例免疫抑制治疗升级,4例免疫抑制药物降级。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Idiopathic inflammatory myopathies (IIMs) are heterogeneous diseases characterized by skeletal muscle inflammation associated with cutaneous, pulmonary and/or other visceral organ involvement. IVIG has been recommended as an adjunct therapy for IIM patients refractory to conventional therapy. However, IVIG has high resource needs and increased risk of adverse reactions. Subcutaneous immunoglobulin (SCIG) therapy has been used as an alternative to IVIG in primary immunodeficiencies and neuroinflammatory disorders. We assessed the satisfaction, patient preference and effectiveness in IIM patients who transitioned from IVIG to SCIG. METHODS: We retrospectively reviewed consecutive 20 patients with IIM who were transitioned from IVIG to SCIG therapy for >12 months. Patient preference between IVIG and SCIG was surveyed using a questionnaire previously used in studies of neuroinflammatory conditions. In addition, disease flares, changes in immunosuppression, cumulative prednisone doses and global disease activity were evaluated using the Myositis Intention to Treat Index (MITAX) 12 months pre- and post-SCIG initiation. RESULTS: Most patients (78.9%) preferred SCIG over IVIG and preferred home-based therapies to hospital-based therapies. There was no significant difference in global disease activity (MITAX 3.31 vs 3.02) or in cumulative steroid doses 12 months pre- or post-SCIG initiation. Three patients experienced disease flares, five escalated in immunosuppression, while four patients deescalated in immunosuppressive medications. CONCLUSIONS: SCIG is preferred by most patients over IVIG without a substantial increased disease activity or need for additional CS. Future cost-effectiveness studies may provide an additional rationale for utilizing SCIG over IVIG for maintenance therapy for IIM.
引用
- Ma Z, Johnson D, Gniadecki R, et al. Subcutaneous immunoglobulin for patients with idiopathic inflammatory myopathies: a real-world, single-centre experience. Rheumatology (Oxford). 2024. PMID: 37796840. doi:10.1093/rheumatology/kead521
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。